Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Julie M. Vose, MD
University of Nebraska
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Auxilio Mutuo
Hato Rey, Puerto Rico
- Arizona Oncology Associates - Craycroft Road Offices
Tucson, Arizona, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Usc/norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States
- Rocky Mountain Cancer Centers - Colorado Springs
Colorado Springs, Colorado, United States
- Rocky Mountain Cancer Centers - Denver Midtown
Denver, Colorado, United States
- Delaware Clinical & Laboratory Physicians
Newark, Delaware, United States
- Pasco, Hernando Oncology Associates, P.A.
New Port Richey, Florida, United States
- Hematology-Oncology Associates of Illinois
Chicago, Illinois, United States
- Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
- Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, United States
- Dana-Farber/harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Unmc Eppley Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska, United States
- North Shore University Hospital
Manhasset, New York, United States
- Suny Upstate Medical University Hospital
Syracuse, New York, United States
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States
- Piedmont Hematology-Oncology Associates
Winston-Salem, North Carolina, United States
- Gabrail Cancer Center - Canton Office
Canton, Ohio, United States
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
- Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
Cleveland, Ohio, United States
- Cancer Care Associates-West
Oklahoma City, Oklahoma, United States
- Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, United States
- Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
- Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina, United States
- Baylor University Medical Center
Dallas, Texas, United States
- University of Texas - Md Anderson Cancer Center
Houston, Texas, United States
- Fairfax Northern Virginia Hematology Oncology, P.C. - Fairfax
Fairfax, Virginia, United States
- Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2003
- Primary completion
- —
- Completion
- —
- Last update posted
- 7 Jul 2009
- Registered enrollment
- —
- Registry id
- NCT00069966
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.